Crescent Biopharma (CBIO) Enterprise Value (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Enterprise Value of -$171.6 million for Q2 2026, down 12.42% year-over-year from -$195.9 million in Q2 2025, and up 9.3% quarter-over-quarter from -$189.2 million in Q1 2026.
Crescent Biopharma (CBIO) Enterprise Value (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Enterprise Value for 14 consecutive years, with -$171.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 12.42% year-over-year to -$171.6 million; the TTM figure through Jun 2026 stood at -$171.6 million (down 12.42% YoY), while the FY2025 annual figure was -$213.2 million, down 513.22% from the prior year.
- Enterprise Value grew to -$171.6 million in Q2 2026 per CBIO's latest filing, from -$189.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$14.4 million in Q3 2024 and bottomed at -$213.2 million in Q4 2025.
- Historically, Enterprise Value has averaged -$79.8 million across 5 years, with a median of -$54.8 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 70.85% — and 2025, when it sank 825.69%.
- Crescent Biopharma's Enterprise Value stood at -$47.9 million in 2022, then climbed by 12.7% to -$41.8 million in 2023, then gained by 16.81% to -$34.8 million in 2024, then plunged by 513.22% to -$213.2 million in 2025, then grew by 19.51% to -$171.6 million in 2026.
- Business Quant data shows CBIO's Enterprise Value at -$171.6 million in Q2 2026, -$189.2 million in Q1 2026, and -$213.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -171.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -171.60 Mn |
| Mar 31, 2026 | -189.20 Mn |
| Dec 31, 2025 | -213.19 Mn |
| Sep 30, 2025 | -133.27 Mn |
| Mar 31, 2025 | -22.43 Mn |
| Dec 31, 2024 | -34.77 Mn |
| Sep 30, 2024 | -14.39 Mn |
| Jun 30, 2024 | -22.39 Mn |
| Mar 31, 2024 | -31.30 Mn |
| Dec 31, 2023 | -41.79 Mn |
| Sep 30, 2023 | -49.41 Mn |
| Jun 30, 2023 | -58.04 Mn |
| Mar 31, 2023 | -65.00 Mn |
| Dec 31, 2022 | -47.87 Mn |
| Sep 30, 2022 | -51.60 Mn |
| Jun 30, 2022 | -60.24 Mn |
| Mar 31, 2022 | -76.52 Mn |
| Dec 31, 2021 | -90.25 Mn |
| Sep 30, 2021 | -101.92 Mn |
| Jun 30, 2021 | -118.85 Mn |